ABSTRACT

Introduction Following the discovery of various effects on skin function by modifying endocannabinoid systems, multiple preclinical studies have revealed the promise of cannabis and cannabinoids in the treatment of a variety of skin diseases. However, its clinical efficacy is still debated.

Methods and analysis The protocol has been prepared using the Preferred Items for Systematic Review and Meta-analysis Protocols guidelines. A systematic search will be conducted using PubMed, EMBASE, SCOPUS, the Cochrane Central Register of Controlled Trials and Web of Science. We will include randomised controlled trials and observational studies investigating alterations to dermatological characteristics following administration of cannabis and cannabinoids for dermatological diseases and disorders. The two reviewers will perform both the title and abstract and full-text screenings. The Cochrane Risk-of-Bias 2 and ROBINS-I tools will be used to evaluate the risk of bias. If a group of comparable studies for each quantitative outcome can be discovered, we will conduct a random effects meta-analysis. We will investigate heterogeneity using a combination of visual inspection of the forest plot, the Cochran’s Q test and Higgins’ test [I2]. Sensitivity analyses will be performed to assess the statistical robustness of the primary outcome. To evaluate a publication bias, the Egger’s regression asymmetry test and funnel plots will be considered.

Ethics and dissemination This study does not require ethical approval because no original data will be collected. The findings will be presented at conferences and published in peer-reviewed journals.

PROSPERO registration number CRD42023397189.

INTRODUCTION

Skin is the largest human organ and is essential for organism survival. It is the first line of immunological and physical protection against the external environment, including heat control and retention of hydration. A substantial part of the population is affected by skin diseases that have significant effects on the quality of life of sufferers.

The endocannabinoid system (ECS), a complex neuromodulatory signalling network, maintains homeostasis and the balance of multiple biological functions by binding ligands (endocannabinoids) to receptors in the nervous system and peripheral organs. Cannabinoids and active components of Cannabis sativa, which were found to mimic endocannabinoid signalling and influence receptor expression, have gained interest as potential treatment for various diseases. The growing legalisation of medicinal cannabis and cannabinoids led to the search for medicinal use in clinical practice. The Food and Drug Administration currently approves the use of cannabinoid to alleviate pain and spasticity in multiple sclerosis and the treatment of chemotherapy-induced nausea and vomiting in patients with cancer.

Modulation of the activity of the ECS may influence several types of skin disease, including atopic dermatitis, psoriasis, acne and skin tumours, according to the aetiology of the diseases. Furthermore, cannabis has been found to possess anti-inflammatory and anti-pruritic properties as well as a few more uncommon ones like anti-hydrosis. This makes the cannabinoids and
active components of *Cannabis sativa* promising for the therapeutic treatment of the skin disorders mentioned above. Given the insufficient quality clinical studies on this topic, this systematic review aims to examine the efficacy of cannabis and cannabinoids in alleviating dermatological conditions and diseases by highlighting current and historical attempts to collect robust clinical data and identify knowledge gaps.

**MATERIALS AND METHODS**

The protocol followed the Preferred Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) guidelines.

**Study selection**

Any randomised controlled trials and observational studies including cross-sectional studies, case–control studies or cohort studies that investigate the efficacy or effectiveness of any form of medical cannabis or cannabinoid in alleviating dermatological conditions or diseases will be included. Exclusion criteria are (1) in vitro studies, case report, protocol, review article, guideline, editorial, commentary and letter to editor, (2) non-peer-reviewed studies, (3) animal studies and (4) studies published in non-English.

**Study outcomes**

1. Generic outcomes used to assess improvement in skin conditions:
   a. Subjective clinical or patient-reported outcomes such as pruritus score, erythema grade and quality of life.
   b. Objective evaluation using standard instruments such as transepidermal water loss, lipid analysis and skin topography evaluation.
2. Disease-specific composite scores, mixed subjective and objective outcomes, such as Psoriasis Area Severity Index for psoriasis, Eczema Area and Severity Index and SCORing Atopic Dermatitis for atopic dermatitis, etc.

**Search strategy**

We will search through five databases: PubMed, EMBASE, SCOPUS, Cochrane Central Register of Controlled Trials and Web of Science published from onset until 9 November 2022 which will be updated to prior manuscript submission. The search strategy constructed by two health information specialists with systematic review experience will combine search terms and subject headings related to ‘cannabis’, ‘cannabaceae’, ‘cannabinoids’, ‘dronabinol’, ‘dermatology’, ‘skin’ and ‘ulcer’ (online supplemental file 1).

**Study records**

**Data management**

After deriving the studies via the mentioned database, we will import them into Covidence systematic review software, which deduplicates studies and facilitates study selection.

**Selection process**

The titles and abstracts of the identified citations will be evaluated by independent paired reviewers, and initially, the abstracts that do not report the therapeutic effects of cannabis and cannabinoids in dermatological conditions or diseases will be eliminated.

The included studies will then undergo full-text review and the final included study will be selected based on all eligibility criteria. Reasons for study exclusion in this step will be recorded. When differences could not be resolved through dialogue, an adjudicator will be brought in to assist. The PRISMA 2020 flow chart will be created to illustrate the workflow.

**Data collection and management**

The data extraction criteria will be refined prior to data collection to ensure consistency among reviewers. The extracted data includes (1) study characteristics including authors, year of publication, study design, journal, contact information, country and funding, (2) participant information including mean age, sex, number of participants, type and baseline severity of skin diseases or conditions, (3) treatment details including the kind of medical cannabinoid used, additional constituents of intervention products, route of administration and the length of treatment, (4) control preparation, route of administration and duration of application, (5) dermatological improvement incorporating results and time points of reported outcome, (6) missing data, (7) interpretation and discussion and (8) all relevant text, tables and figures. We will contact the corresponding authors of the included studies to obtain incompletely reported data. If no response is received within 14 days, studies will be carried out using the available data.

**Risk of bias**

The two reviewers will independently assess the risk of bias. The risk of bias of all randomised controlled studies will be assessed using the Cochrane Risk-of-Bias 2, including the randomisation process, allocation concealment, blinding of participants, outcome evaluation, fully addressed outcome data, selective outcome reporting and other sources of bias. Using ROBINS-1, bias of all non-randomised controlled studies was evaluated, including bias due to confounding, selection bias, bias in classification of interventions, bias due to deviations from intended interventions, bias due to missing data, bias in measurement of outcomes and bias in selection of the reported result. When a dispute between two reviewers cannot be resolved through dialogue, an adjudicator will be called in to aid.

**Data synthesis**

**Qualitative synthesis**

We will qualitatively analyse the studies and their results in accordance with Standard 4.2 and Chapter
4 of Finding What Works in Healthcare: Standards for Systematic Review. We will analyse the studies following the study outcomes, discuss the details of each performance of cannabis and cannabinoids in alleviating dermatological conditions or diseases and evaluate the risk of bias.

Quantitative synthesis
If the study includes a control group, we will evaluate the outcomes between case and control, as well as between pre-cannabinoids and post-cannabinoids applications. If the study lacks a control group, we will only compare pre-performance and post-performance. We will combine the study results for each outcome reported in common by two or more studies using the standard mean difference (SMD) method for continuous outcomes and the relative risk method for dichotomous outcomes. For continuous outcomes in studies with controls, we will use the SMD of the difference between the case’s pre-performance and post-performance and the control’s pre-performance and post-performance to eliminate baseline heterogeneity between case and control. To compare findings before and after cannabinoid treatment, we will use the SMD of outcomes before and after cannabinoid administration. The pooled effect sizes and 95% CIs will be calculated using random effects models.

For continuous outcomes measured on different scales, in addition to the SMD approach for standardisation, we will attempt to employ the OR method by specifying the cut-off of the outcome and converting all continuous measures to binary scale, which are ‘improvement’ and ‘no improvement’. We will seek the raw data from the respective authors by contacting them. If we were unable to get the response within 14 days, we will perform the analysis using only the available data.

RevMan V.5.4 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark) will be used to perform the meta-analysis. P value <0.05 will be considered statistically significant.

Assessment of heterogeneity
Heterogeneity will be determined using the Cochrane’s Q test (a p value of 0.10 indicated heterogeneity) and the Higgins’ test [12] (less than 25%: low heterogeneity, 25–75%: moderate heterogeneity, more than 75%: high heterogeneity).26

Sensitivity analysis and publication bias
Sensitivity analyses will examine redoing the meta-analysis by removing one research at a time to assess the statistical robustness of the primary outcome. The Egger’s regression asymmetry test and funnel plots will be considered to assess publication bias using R V.4.0.1 if the number of identified studies is fewer than 10.

Expected dates for research
1 September 2023 to 31 November 2023.

Ethics and dissemination
Because no original data will be collected, this study does not require ethical approval. The results will be presented at conferences and published in journals with peer review.

Patients and public involvement
Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

IMPLICATIONS
This systematic review and meta-analysis aims to provide a comprehensive summary of the therapeutic effects of cannabis and cannabinoids on dermatological conditions and diseases. Previous scoping studies and systematic reviews may have focused on different types of skin disorders: nevertheless, quantitative meta-analysis and systematic reviews based primarily on skin problems tend to be restricted, particularly when dividing the measured results into subjective, objective and disease-specific composite scores. Reporting the efficacy of the treatment in the aforementioned characteristics can make the findings in this study easier to apply, since this quantitative reporting can be easier to comprehend and reproduce for future extended research and decreases the biased bias of the authors, and because a skin condition is identified in many skin diseases. This informs clinicians and patients about the efficacy of cannabis and cannabinoids in skin disorders and identifies information gaps that may lead to the creation of a new alternative therapy for dermatological diseases.

Author affiliations
1Center of Excellence in Preventive & Integrative Medicine and Department of Preventive and Social Medicine, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand
2Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA
3Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA
4Department of Infectious Diseases, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA
5Clinical Research Center, Bumrungrad International Hospital, Bangkok, Thailand

Twitter Krit Pongpirul @doctorkrit
Contributors PS, TN, CS, KC and KP conceived of the study and initiated the study design. PS wrote original draft. KP reviewed and edited the draft. KP supervised. All authors contributed to the refinement of the study protocol.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content...
REFERENCES